Research-Article

You have full text access to this OnlineOpen article

Selective Modification of Bone Quality by PTH, Pamidronate, or Raloxifene†

  1. Tara C Brennan,
  2. René Rizzoli,
  3. Patrick Ammann*

Article first published online: 8 DEC 2008

DOI: 10.1359/jbmr.081227

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 24, Issue 5, pages 800–808, May 2009

Additional Information

How to Cite

Brennan, T. C., Rizzoli, R. and Ammann, P. (2009), Selective Modification of Bone Quality by PTH, Pamidronate, or Raloxifene. J Bone Miner Res, 24: 800–808. doi: 10.1359/jbmr.081227

Author Information

  1. Division of Bone Diseases [WHO Collaborating Centre for Osteoporosis Prevention], Department of Rehabilitation and Geriatrics, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland

*Address correspondence to: Patrick Ammann, MD, Division of Bone Diseases, Department of Rehabilitation and Geriatrics, Geneva University Hospital, CH-1211 Geneva 14, Switzerland

  1. †

    The authors state that they have no conflicts of interest.

Publication History

  1. Issue published online: 4 DEC 2009
  2. Article first published online: 8 DEC 2008
  3. Manuscript Accepted: 5 DEC 2008
  4. Manuscript Revised: 17 NOV 2008
  5. Manuscript Received: 18 JUL 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (217K)

REFERENCES

  • 1
    Riggs BL, Khosla S, Melton LJ 2002 Sex steriods and the construction and conservation of the adult skeleton. Endocr Rev 23: 279–302.
  • 2
    Kanis JA 2002 Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359: 1929–1936.
  • 3
    Riggs BL, Parfitt AM 2005 Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20: 177–184.
    Direct Link:
  • 4
    Delmas PD 2002 Treatment of postmenopausal osteoporosis. Lancet 359: 2018–2026.
  • 5
    Russell R, Watts N, Ebetino F, Rogers M 2008 Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19: 733–759.
  • 6
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 1475–1480.
  • 7
    Ammann P, Rizzoli R, Bonjour JP 1998 Preclinical evaluation of new therapeutic agents for osteoporosis. In: MeunierPJ (ed.) Osteoporosis: Diagnosis and management. Martin Dunitz, London, UK, 257–273.
  • 8
    Christiansen C, Lindsay R 1990 Estrogens, bone loss and preservation. Osteoporos Int 1: 7–13.
  • 9
    Riggs BL, Hartmann LC 2003 Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348: 618–629.
  • 10
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation I 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282: 637–645.
  • 11
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH, Mellstrom D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441.
  • 12
    Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 26: 688–703.
  • 13
    Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R 2003 Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 5212–5220.
  • 14
    Zanchetta BC Jr , Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL 2003 Effects of teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18: 539–543.
    Direct Link:
  • 15
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, for the Treatment of Osteoporosis with Parathyroid Hormone Study Group 2007 Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Ann Intern Med 146: 326–339.
  • 16
    Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R 2007 Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357: 2028–2039.
  • 17
    Saville PD 1969 Changes in skeletal mass and fragility with castration in the rat: A model for osteoporosis. Am J Geriatr Soc 17: 155–166.
  • 18
    Wronski TJ, Lowry PL, Walsh CC, Ignaszewski LA 1985 Skeletal alterations in ovariectomized rats. Calcif Tissue Int 37: 324–328.
  • 19
    Turner RT, Vandersteenhoven JJ, Bell NH 1987 The effects of ovariectomy and 17 beta-estradiol on cortical bone histomorphometry in growing rats. J Bone Miner Res 2: 115–122.
    Direct Link:
  • 20
    Bagi CM, DeLeon E, Ammann P, Rizzoli R, Miller SC 1996 Histo-anatomy of the proximal femur in rats: Impact of ovariectomy on bone mass, structure, and stiffness. Anat Rec 245: 633–644.
    Direct Link:
  • 21
    Bagi CM, Ammann P, Rizzoli R, Miller SC 1997 Effect of estrogen deficiency on cancellous and cortical bone structure and strength of the femoral neck in rats. Calcif Tissue Int 61: 336–344.
  • 22
    Turner CCH, Burr DDB, Hock JJM, Brommage RR, Sato MM 2001 The effects of PTH (1–34) on bone structure and strength in ovariectomized monkeys. Adv Exp Med Biol 496: 165–179.
  • 23
    Lees CJ, Register TC, Turner CH, Wang T, Stancill M, Jerome CP 2002 Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. J North Am Menopause Soc 9: 320–328.
  • 24
    Ammann P, Rizzoli R, Slosman D, Bonjour JP 1992 Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy x-ray absorptiometry. J Bone Miner Res 7: 311–316.
    Direct Link:
  • 25
    Ammann P, Badoud I, Barraud S, Dayer R, Rizzoli R 2007 Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 22: 1419–1425.
    Direct Link:
  • 26
    Laib A, Barou O, Vico L, Lafage-Proust MH, Alexandre C, Rügsegger P 2000 3D micro-computed tomography of trabecular and cortical bone architecture with application to a rat model of immobilisation osteoporosis. Med Biol Eng Comput 38: 326–332.
  • 27
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH 2006 Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21: 1785–1790.
    Direct Link:
  • 28
    Garnero P, Bauer DC, Mareau E, Bilezikian JP, Greenspan SL, Rosen C, Black D 2008 Effects of parathyroid hormone and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: The PaTH study. J Bone Miner Res 23: 1442–1448.
    Direct Link:
  • 29
    Kim D-G, Hunt C, Zauel R, Fyhrie D, Yeni Y 2007 The effect of regional variations of the trabecular bone properties on the compressive strength of human vertebral bodies. Ann Biomed Eng 35: 1907–1913.
  • 30
    Ladinsky GA, Vasilic B, Popescu AM, Wald M, Zemel BS, Snyder PJ, Loh L, Song HK, Saha PK, Wright AC, Wehrli FW 2008 Trabecular structure quantified with the MRI-based virtual bone biopsy in postmenopausal women contributes to vertebral deformity burden independent of areal vertebral BMD. J Bone Miner Res 23: 64.
    Direct Link:
  • 31
    Wehrli FW, Ladinsky GA, Jones C, Benito M, Magland J, Vasilic B, Popescu AM, Zemel B, Cucchiara AJ, Wright AC, Song HK, Saha PK, Peachey H, Snyder PJ 2008 In vivo magnetic resonance detects rapid remodeling changes in the topology of the trabecular bone network after menopause and the protective effect of estradiol. J Bone Miner Res 23: 730.
    Direct Link:
  • 32
    Boivin G, Meunier PJ 2002 Effects of bisphosphonates on matrix mineralisation. J Musculoskelet Neuronal Interact 6: 538–543.
  • 33
    Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29: 185–191.
  • 34
    Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, Phipps R, Klaushofer K 2006 Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 21: 1106–1112.
    Direct Link:
  • 35
    Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW 1999 Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 10: 330–336.
  • 36
    Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw K-T, Zhao Q, Agnusdei D, Cauley JA 2008 Effects of raloxifene on fracture risk in postmenopausal women: The raloxifene use for the heart trial. J Bone Miner Res 23: 112–120.
    Direct Link:
  • 37
    Allen MR, Iwata K, Sato M, Burr DB 2006 Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 39: 1130–1135.
  • 38
    Allen MR, Hogan HA, Hobbs WA, Koivuniemi AS, Koivuniemi MC, Burr DB 2007 Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone. Endocrinology 148: 3908–3913.
  • 39
    Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME 2004 Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: Results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 255: 503–511.
    Direct Link:
  • 40
    Sato M, Bryant HU, Iversen P, Helterbrand J, Smietana F, Bemis K, Higgs R, Turner CH, Owan I, Takano Y, Burr DB 1996 Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J Pharmacol Exp Ther 279: 298–305.
  • 41
    Viguet-Carrin S, Garnero P, Delmas P 2006 The role of collagen in bone strength. Osteoporos Int 17: 319–336.
  • 42
    Burr DB 2002 The contribution of the organic matrix to bone's material properties. Bone 31: 8–11.
  • 43
    Mann V, Huber C, Kogianni G, Collins F, Noble B 2007 The antioxidant effect of estrogen and selective estrogen receptor modulators in the inhibition of osteocyte apoptosis in vitro. Bone 40: 674–684.
  • 44
    van Essen H, Holzmann P, Blankenstein M, Lips P, Bravenboer N 2007 Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women. Calcif Tissue Int 81: 183–190.
  • 45
    Girotra M, Rubin M, Bilezikian J 2006 The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 7: 113–121.
  • 46
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18: 1932–1941.
    Direct Link:
  • 47
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetić K, Müller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16: 1846–1853.
    Direct Link:
View Full Article (HTML) Get PDF (217K)